Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial

K V Grooteman, E J M van Geenen, J P H Drenth, K V Grooteman, E J M van Geenen, J P H Drenth

Abstract

Introduction: Gastrointestinal angiodysplasias are an important cause of difficult-to-manage bleeding, especially in older patients. Endoscopic coagulation of angiodysplasias is the mainstay of treatment, but may be difficult for small bowel angiodysplasias because of the inability to reach them for endoscopic intervention. Some patients are red blood cell (RBC) transfusion dependent due to frequent rebleeding despite endoscopic treatment. In small cohort studies, octreotide appears to decrease the number of bleeding episodes in patients with RBC transfusion dependency due to gastrointestinal angiodysplasias. This trial will assess the efficacy of octreotide in decreasing the need for RBC transfusions and parenteral iron in patients with anaemia due to gastrointestinal bleeding of small bowel angiodysplasias despite endoscopic intervention.

Study design: Randomised controlled, superiority, open-label multicentre trial.

Participants: 62 patients will be included with refractory anaemia due to small bowel angiodysplasias, who are RBC transfusion or iron infusion dependent despite endoscopic intervention and oral iron supplementation.

Intervention: Patients will be randomly assigned (1:1) to standard care or 40 mg long-acting octreotide once every 4 weeks for 52 weeks, in addition to standard care. The follow-up period is 8 weeks.

Main outcome measures: The primary outcome is the difference in the number of blood and iron infusions between the year prior to inclusion and the treatment period of 1 year. Important secondary outcomes are the per cent change in the number of rebleeds from baseline to end point, adverse events and quality of life.

Ethics and dissemination: The trial received ethical approval from the Central Committee on Research Involving Human Subjects and from the local accredited Medical Research Ethics Committee of the region Arnhem-Nijmegen, the Netherlands (reference number: 2014-1433). Results will be published in a peer-reviewed journal and presented at international conferences.

Trial registration number: NCT02384122; Pre-results.

Keywords: CLINICAL PHARMACOLOGY.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Study design of the OCEAN trial. IC, informed consent; PL, physical examination, laboratory tests, safety assessment; Q, assessment of PSQ-An and SF-36 questionnaires.

References

    1. Foutch PG, Rex DK, Lieberman DA. Prevalence and natural history of colonic angiodysplasia among healthy asymptomatic people. Am J Gastroenterol 1995;90:564–7.
    1. Richter JM, Christensen MR, Colditz GA et al. . Angiodysplasia. Natural history and efficacy of therapeutic interventions. Dig Dis Sci 1989;34:1542–6.
    1. Gupta N, Longo WE, Vernava AM III. Angiodysplasia of the lower gastrointestinal tract: an entity readily diagnosed by colonoscopy and primarily managed nonoperatively. Dis Colon Rectum 1995;38: 979–82. 10.1007/BF02049736
    1. Jackson CS, Gerson LB. Management of gastrointestinal angiodysplastic lesions (GIADs): a systematic review and meta-analysis. Am J Gastroenterol 2014;109:474 10.1038/ajg.2014.19
    1. Sami SS, Al-Araji SA, Ragunath K. Review article: gastrointestinal angiodysplasia—pathogenesis, diagnosis and management. Aliment Pharmacol Ther 2014;39:15–34. 10.1111/apt.12527
    1. Dray X, Camus M, Coelho J et al. . Treatment of gastrointestinal angiodysplasia and unmet needs. Dig Liver Dis 2011;43:515–22. 10.1016/j.dld.2010.12.007
    1. Holleran G, Hall B, Hussey M et al. . Small bowel angiodysplasia and novel disease associations: a cohort study. Scand J Gastroenterol 2013;48:433–8. 10.3109/00365521.2012.763178
    1. Junquera F, Feu F, Papo M et al. . A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001;121:1073 10.1053/gast.2001.28650
    1. Lewis BS, Salomon P, Rivera-MacMurray S et al. . Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992;15:99–103. 10.1097/00004836-199209000-00004
    1. Cutsem EV, Rutgeert P, Vantrappen G. Long-term effect of hormonal therapy for bleeding gastrointestinal vascular malformations. Eur J Gastroenterol Hepatol 1993;5:439–43. 10.1097/00042737-199306000-00008
    1. Barkin JS, Ross BS. Medical therapy for chronic gastrointestinal bleeding of obscure origin. Am J Gastroenterol 1998;93:1250–4. 10.1111/j.1572-0241.1998.404_i.x
    1. van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen–progesterone. Lancet 1990;335:953–5. 10.1016/0140-6736(90)91010-8
    1. Ge ZZ, Chen HM, Gao YJ et al. . Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011;141:1629–37. 10.1053/j.gastro.2011.07.018
    1. Kurosaki M, Saegert W, Abe T et al. . Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res 2008;30:518–22.
    1. Ludwig D, Terai S, Brüning A et al. . Long-term haemodynamic effects of octreotide on postprandial splanchnic hyperemia in humans: a placebo controlled echo-Doppler study. Aliment Pharmacol Ther 1999;13:1119–29. 10.1046/j.1365-2036.1999.00583.x
    1. Junquera F, Saperas E, Videla S et al. . Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007;102:254–60. 10.1111/j.1572-0241.2007.01053.x
    1. Scaglione G, Pietrini L, Russo F et al. . Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Aliment Pharmacol Ther 2007;26:935–42. 10.1111/j.1365-2036.2007.03435.x
    1. Nardone G, Rocco A, Balzano T et al. . The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999;13:1429–36. 10.1046/j.1365-2036.1999.00647.x
    1. Molina Infante J, Pérez Gallardo B, Hernández Alonso M et al. . Octreotide long acting release for severe obscure gastrointestinal haemorrhage in elderly patients with serious comorbidities. Med Clin (Barc) 2009;133:667–70. 10.1016/j.medcli.2009.07.013
    1. Bon C, Aparicio T, Vincent M et al. . Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Aliment Pharmacol Ther 2012;36:587–93. 10.1111/apt.12000
    1. Holleran G, Hall B, Breslin N et al. . Long-acting somatostatin analogues provide significant beneficial effect in patients with refractory small bowel angiodysplasias: results from a proof of concept open label mono-centre trial. United Eur Gastroenterol J 2016;4:70–6. 10.1177/2050640614559121
    1. Benamouzig R. Essai de phase II randomisé évaluant l'efficacité du pasiréotide pour le traitement des angiodysplasies digestives en échec de traitement endoscopique. Presentation JFHOD; 2016.
    1. Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 2011;28:825–41. 10.1007/s12325-011-0062-9
    1. Temmerman F, Gevers T, Ho TA et al. . Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol Ther 2013;38:397–406. 10.1111/apt.12384
    1. CBO (Centraal BegeleidingsOrgaan) Guideline: bloodtransfusion. Utrecht, 2011. (accessed Jan 2016).
    1. Villanueva C, Colomo A, Bosch A et al. . Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11–21. 10.1056/NEJMoa1211801
    1. Brown C, Subramanian V, Wilcox CM et al. . Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Dig Dis Sci 2010;55:2129–34. 10.1007/s10620-010-1193-6
    1. Klímová K, Padilla-Suárez C, Giménez-Manzorro Á et al. . Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: cost-effectiveness study. Rev Esp Enferm Dig 2015;107:79–88.
    1. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992;1:113–19.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa